Skip to main navigation Skip to search Skip to main content

Gallbladder disease, cholecystectomy, and pancreatic cancer risk in the International Pancreatic Cancer Case-Control Consortium (PanC4)

  • Valentina Rosato
  • , Eva Negri
  • , Cristina Bosetti
  • , Núria Malats
  • , Paulina Gomez-Rubio
  • , Pan Gen EU Consortium
  • , Patrick Maisonneuve
  • , Anthony B. Miller
  • , H. Bas Bueno-De-Mesquita
  • , Peter A. Baghurst
  • , Witold Zatonski
  • , Gloria M. Petersen
  • , Ghislaine Scelo
  • , Ivana Holcatova
  • , Eleonora Fabianova
  • , Diego Serraino
  • , Sara H. Olson
  • , Jesús Vioque
  • , Pagona Lagiou
  • , Eric J. Duell
  • Paolo Boffetta, Carlo La Vecchia
  • IRCCS Foundation
  • University of Milan
  • IRCCS Istituto di ricerche farmacologiche Mario Negri - Milano, Bergamo, Ranica
  • Spanish National Cancer Research Centre (CNIO)
  • IRCCS Istituto Europeo di Oncologia - Milano
  • University of Toronto
  • National Institute of Public Health and the Environment
  • Utrecht University
  • Imperial College London
  • Women's and Children's Hospital Adelaide
  • Health Promotion Foundation
  • Maria Sklodowska-Curie Institute of Oncology
  • Mayo Clinic Rochester, MN
  • International Agency for Research on Cancer
  • Charles University
  • Regional Authority of Public Health
  • Catholic University in Ruzomberok
  • IRCCS Centro di Riferimento Oncologico - Aviano PN
  • Memorial Sloan-Kettering Cancer Center
  • Alicante Hospital
  • CIBER Epidemiología y Salud Pública (CIBERESP)
  • National and Kapodistrian University of Athens
  • Harvard University
  • Parc Taulí Hospital Universitari

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background The association among gallbladder disease, cholecystectomy, and pancreatic cancer is unclear. Moreover, time interval between gallbladder disease or cholecystectomy and pancreatic cancer diagnosis is not considered in most previous studies. Aim To quantify the association among gallbladder disease, cholecystectomy, and pancreatic cancer, considering time since first diagnosis of gallbladder disease or cholecystectomy. Methods We used data from nine case-control studies within the Pancreatic Cancer Case-Control Consortium, including 5760 cases of adenocarcinoma of the exocrine pancreas and 8437 controls. We estimated pooled odds ratios and the corresponding 95% confidence intervals by estimating study-specific odds ratios through multivariable unconditional logistic regression models, and then pooling the obtained estimates using fixed-effects models. Results Compared with patients with no history of gallbladder disease, the pooled odds ratio of pancreatic cancer was 1.69 (95% confidence interval, 1.51-1.88) for patients reporting a history of gallbladder disease. The odds ratio was 4.90 (95% confidence interval, 3.45-6.97) for gallbladder disease diagnosed <2 years before pancreatic cancer diagnosis and 1.11 (95% confidence interval, 0.96-1.29) when ≥2 years elapsed. The pooled odds ratio was 1.64 (95% confidence interval, 1.43-1.89) for patients who underwent cholecystectomy, as compared to those without cholecystectomy. The odds ratio was 7.00 (95% confidence interval, 4.13-11.86) for a surgery <2 years before pancreatic cancer diagnosis and 1.28 (95% confidence interval, 1.08-1.53) for a surgery ≥2 years before. Conclusions There appears to be no long-term effect of gallbladder disease on pancreatic cancer risk, and at most a modest one for cholecystectomy. The strong short-term association can be explained by diagnostic bias and reverse causation.

Original languageEnglish
Pages (from-to)408-415
Number of pages8
JournalEuropean Journal of Cancer Prevention
Volume29
Issue number5
DOIs
StatePublished - Sep 1 2020

Keywords

  • case-control studies
  • cholecystectomy
  • gallbladder disease
  • pancreatic cancer
  • pooled analysis
  • risk factors

Fingerprint

Dive into the research topics of 'Gallbladder disease, cholecystectomy, and pancreatic cancer risk in the International Pancreatic Cancer Case-Control Consortium (PanC4)'. Together they form a unique fingerprint.

Cite this